• Regulus Therapeutics Announces Changes to Phase 2 Trial for RG-012 in Alport Syndrome
  • Regulus Back on Track with RG-012 Clinical Development for Alport Syndrome
  • Alport Syndrome Foundation’s Virtual Walk Kicks Off June 17
  • New Gene Screening Method, Whole-Exome Sequencing, Seen to Help in Diagnosing Alport Syndrome
  • Researchers Identify New Gene Mutations Related to Alport Syndrome
  • Reata Tests Bardoxolone Methyl as Possible Treatment for Loss of Kidney Activity in Alport Syndrome
  • Single-point Mutation in Critical Gene Seen to Cause Key Alport Symptoms
  • Alport Syndrome Foundation Among 14 Groups Awarded Global Genes’ RARE Patient Grants
  • Regulus Drug Candidate RG-012 to Treat Kidney Damage in Alport Patients Begins Phase 1 Clinical Trials
  • Report Describes Teenager with 2 Rare Diseases: Alport Syndrome and ANCA-Associated Vasculitis
  • Reata Names Marketing Chief, Continues Recruiting Phase 2/3 Trial Participants
  • Heart Your Kidneys Campaign Includes ‘Tech Tattoos’ to Track Water Intake